Seasonal Affective Disorder |
SAD |
Clinical Trial: An Approved Drug to Study a New Indication for Allergic Rhinitis
This study is no longer recruiting patients.
|
Purpose
The purpose of this trial is to evaluate the efficacy and safety of an investigational drug in adult patients with allergic rhinitis
| Condition | Intervention | Phase |
|---|---|---|
| Rhinitis, Allergic, Seasonal | Drug: MK0476, montelukast sodium | Phase III |
MedlinePlus related topics: Allergy
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Eligibility
Ages Eligible for Study: 15 Years - 64 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Japanese Males and females with a 2-year documented history of seasonal allergic rhinitis symptoms and positive allergy testing(cedar,alder and/or cypress)
Exclusion Criteria:
- Patients with drug-induced rhinitis or non-allergic rhinitis, or patients who used anti-histamine drugs(within 2 weeks) before the start of the observation period.
Location Information
Japan, Chuoku
Call For Site Information, Tokyo, Chuoku, 103-8416, Japan
Study chairs or principal investigators
Medical Monitor, Study Director, Merck
More Information
Study ID Numbers: 2005_038
Last Updated: August 5, 2005
Record first received: August 4, 2005
ClinicalTrials.gov Identifier: NCT00127647
Health Authority: Japan: Ministry of Health, Labor and Welfare
ClinicalTrials.gov processed this record on 2005-08-23
Last Updated: August 5, 2005
Record first received: August 4, 2005
ClinicalTrials.gov Identifier: NCT00127647
Health Authority: Japan: Ministry of Health, Labor and Welfare
ClinicalTrials.gov processed this record on 2005-08-23
Resources
- Ask NOAH About: Seasonal Affective DisorderFact Sheet (New York Online Access to Health, The New York Hospital Cornell Medical Center (NOAH))
- ClinicalTrials.gov: Seasonal Affective Disorder (National Institutes of Health)

Not Signed In -

